Merck
Price & Volume
Stats
See more52W Range | $74.18-$130.29 |
Market Cap | $305.1B |
Shares Short | 31M |
Financials
See moreRevenue (12 Mos) | $65.7B |
Revenue Growth (YoY) | 4.9% |
Gross Profit (12 Mos) | $50.4B |
Diluted EPS | $3.55 |
News
See moreYahoo Finance • yesterday
FDA Approves Merck's KEYTRUDA + Padcev Regimens For Muscle-Invasive Bladder Cancer
Yahoo Finance • 2 days ago
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
Yahoo Finance • 2 days ago
Pfizer wins FDA label expansion for Padcev plus Merck’s Keytruda in bladder cancer
Yahoo Finance • 3 days ago
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
About
CEO | Mr. Robert M. Davis J.D. |
CFO | Ms. Caroline A. Litchfield |
Address | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
Full-Time Employees | 73,000 |